Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration

Wen‐Ho ‐H Chang, Dong‐Juiing ‐J Juang, Shih‐Ku ‐K Lin, Jin‐Ding ‐D Huang, Yw Francis Lam, Michael W. Jann, Ching‐Piao ‐P Chien

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

A single dose of haloperidol decanoate 100 mg was administered to 15 schizophrenic patients. Blood samples were obtained prior to injection, 1 h, 3 h, 6 h, 8 h, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, one week, two weeks, three weeks and four weeks post‐injection. Haloperidol and its reduced metabolite, reduced haloperidol, plasma levels were assayed by HPLC with electrochemical detection. The pharmacokinetic parameters of haloperidol were determined. The mean time of maximal (Tmax) plasma levels for haloperidol was 5·73 ± 0·80 days. The haloperidol plasma levels showed a biexponential decline with an elimination half‐life of 15·78 ± 5·90 days. Reduced haloperidol was rapidly formed from the haloperidol. The Tmax of reduced haloperidol was 7·00 ± 2·35 days. The mean ratio reduced haloperidol/haloperidol was 0·155 ± 0·111. Since the Tmax occurs at approximately six days, a weekly loading dose of haloperidol decanoate is feasible during the transition from oral to depot therapy.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalHuman Psychopharmacology: Clinical and Experimental
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1995

Keywords

  • Haloperidol decanoate
  • haloperidol and reduced haloperidol plasma levels

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Disposition of haloperidol and reduced haloperidol plasma levels after single dose haloperidol decanoate administration'. Together they form a unique fingerprint.

Cite this